Article Sidebar

PDF
Date Published: 25/04/2022
Abstract Views: 384
Views PDF: 150
DOI: https://doi.org/10.51298/vmj.v512i1.2224
Issue
Vol. 512 No. 1 (2022)
Section
Các bài báo
How to Cite
Xuân Hậu, N., & Xuân Hiền N. . (2022). TREATMENT OUTCOMES OF RECURRENT THYROID CANCER. Vietnam Medical Journal, 512(1). https://doi.org/10.51298/vmj.v512i1.2224

TREATMENT OUTCOMES OF RECURRENT THYROID CANCER

Nguyễn Xuân Hậu1,2,, Nguyễn Xuân Hiền2
1 Hanoi Medical University
2 Hanoi Medical University Hospital

Main Article Content

Abstract

Objective: to evaluate clinical outcomes and some features associated with the survival of recurrent thyroid cancer. Subjects and Methods: a retrospective combined with a prospective cohort study of 50 recurrent thyroid cancer patients treated by surgery at Hanoi Medical University Hospital from October 2017 to August 2021. Results: All patients had undergone radical surgery, the rate of total thyroidectomy with neck dissection and bilateral neck dissection were  33.3% and 66.7% respectively. Post-operation complications occurred in 27% of cases, almost in the first week. Treatment with radioactive iodine after surgery was performed in 63% of patients. The median follow-up period was 35 months, a maximum of 86 months. The overall survival rate was 100%, the 5-year DFS rate was 85.1%. The 5-year DFS times were shorter in the invaded, over 45 year olds and radioiodine refractoried. Conclusion: Surgery of recurrent thyroid carcinoma is safe and less complication..

Article Details

Keywords

recurrent thyroid cancer, treatment outcomes

References

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer. 1998;83(12):2638-2648.
2. Edga SB BD, Compton CC AJCC Cancer Staging Manual, 7th Ed. Springer. 2010:1 - 646.
3. David SC. Management of thyroid disease. Chapter 5 (Thyroid Nodule and multinodular gotier). Informa Helthcare USA, New York; 2008.
4. Lang BH, Lee GC, Ng CP, Wong KP, Wan KY, Lo CY. Evaluating the morbidity and efficacy of reoperative surgery in the central compartment for persistent/recurrent papillary thyroid carcinoma. World journal of surgery. 2013;37(12):2853-2859.
5. Schuff KG, Weber SM, Givi B, Samuels MH, Andersen PE, Cohen JI. Efficacy of nodal dissection for treatment of persistent/recurrent papillary thyroid cancer. The Laryngoscope. 2008;118(5):768-775.
6. Tufano RP, Bishop J, Wu G. Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. The Laryngoscope. 2012;122(7):1634-1640.
7. Trần Ngọc Hải. Nghiên cứu đặc điểm lâm sàng, cận lâm sàng và kết quả điều trị của bệnh ung thư giáp trạng tái phát tại bệnh viện K. Đại học Y Hà Nội, Hà Nội. 2008.
8. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. The American journal of medicine. 1994;97(5):418-428.
9. Nixon IJ, Whitcher MM, Palmer FL, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid : official journal of the American Thyroid Association. 2012;22(9):884-889.